Alexandria Real Estate Equities (ARE)
Real Estate · Life Science Real Estate (Specialized REIT)
A life science real estate REIT developing collaborative Megacampus ecosystems for biotech, pharma, and research institutions across premier innovation hubs.
What Alexandria Real Estate Equities does
Alexandria Real Estate Equities is a REIT that owns, operates, and develops Class A/A+ real estate properties designed for life science companies, research institutions, and biotech tenants. The company owns approximately 39.4 million RSF of operating and development properties across major life science innovation clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and NYC. Alexandria creates collaborative "Megacampus" environments that enable scientific innovation and talent recruitment for multinational pharma companies, biotechnology firms, academic institutions, government research agencies, and venture capital firms. The company also provides strategic capital to life science companies through its venture capital platform.
Themes: ["Life science real estate","Biotech infrastructure","Innovation cluster development","Collaborative research environments","Venture capital / strategic capital","Real estate development"]
Fundamentals
- Price$48.51 as of 2026-07-09 close
- Market cap$8.5B as of 2026-07-10
- 1-year return-37.6% as of 2026-07-09 close
- Net margin-36.3% as of 2026-07-10
- Gross margin+69.3% as of 2026-07-10
- ROE-6.5% as of 2026-07-10
- Debt / equity0.80 as of 2026-07-10
- Revenue growth (YoY)-9.5% as of 2026-07-10
- Beta1.18 as of 2026-07-10
Dividend: yield +6.0%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Occupancy decline risk: Operating occupancy fell to 90.9% as of December 31, 2025, below the company's 10-year average of 95%, indicating softening tenant demand and potential revenue pressure.","Dividend sustainability and shareholder return pressure: The company reduced its quarterly dividend by 45% in December 2025, and filings indicate that further reductions may negatively impact stock price; distributions depend on cash from operations and asset sales.","Negative profitability and cash flow strain: The company posted a -36.32% net margin and -9.53% revenue growth YoY, with stock returns down 34.2% over one year, signaling operational challenges and market stress in the life science real estate sector."]
Competitors & peers
- Kilroy Realty Corporation (KRC)
- Paramount Group, Inc. (PGRE)
- Columbia Property Trust (CXP)
- Equity Commonwealth (EQC)
- Brandywine Realty Trust (BDN)
- SL Green Realty Corp (SLG)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.